MEDIPOST Inc. Announces $140 Million in Funding to Accelerate Late-Stage Clinical Development
MEDIPOST Inc., a biotechnology company developing allogeneic, umbilical cord blood-derived stem cell therapies for inflammation-driven degenerative diseases, today announced that its parent company, MEDIPOST Co., Ltd., has closed on $140 million in funding.
